News
EPRX
2.500
+3.73%
0.090
Weekly Report: what happened at EPRX last week (1014-1018)?
Weekly Report · 2d ago
Health Rounds: Steroid injection relieves knee arthritis pain for months
Reuters · 10/15 19:49
Eupraxia’s EP-104IAR Gains Attention in Rheumatology
TipRanks · 10/15 11:45
Weekly Report: what happened at EPRX last week (1007-1011)?
Weekly Report · 10/14 12:56
Eupraxia Pharmaceuticals Highlights Innovation at UEG Week 2024
TipRanks · 10/10 11:27
Weekly Report: what happened at EPRX last week (0930-1004)?
Weekly Report · 10/07 12:41
Eupraxia Pharmaceuticals Enhances Leadership Team
TipRanks · 10/02 21:27
Eupraxia Pharmaceuticals names Amanda Malone as Chief Scientific Officer
TipRanks · 10/02 21:05
EUPRAXIA PHARMACEUTICALS STRENGTHENS SENIOR MANAGEMENT TEAM
Reuters · 10/02 21:01
Weekly Report: what happened at EPRX last week (0923-0927)?
Weekly Report · 09/30 12:30
Weekly Report: what happened at EPRX last week (0916-0920)?
Weekly Report · 09/23 12:28
Eupraxia Pharmaceuticals Showcases Innovative Therapy at ISDE Congress
TipRanks · 09/19 21:39
Weekly Report: what happened at EPRX last week (0909-0913)?
Weekly Report · 09/16 12:14
Eupraxia’s EP-104GI Shows Promise in EoE Trial
TipRanks · 09/11 11:27
EUPRAXIA PHARMACEUTICALS ANNOUNCES DATA FROM RESOLVE PHASE 1B/2A TRIAL OF EP-104GI FOR TREATMENT OF EOSINOPHILIC ESOPHAGITIS
Reuters · 09/11 11:00
EUPRAXIA PHARMACEUTICALS INC: TRIAL MET ITS PRIMARY ENDPOINT AND THREE OF FOUR SECONDARY ENDPOINTS
Reuters · 09/11 11:00
EUPRAXIA PHARMACEUTICALS INC - NO SERIOUS ADVERSE EVENTS REPORTED IN FOUR FULLY-DOSED COHORTS
Reuters · 09/11 11:00
Weekly Report: what happened at EPRX last week (0902-0906)?
Weekly Report · 09/09 12:30
Eupraxia Pharma Showcases Innovation at Global Conference
TipRanks · 09/04 11:27
Weekly Report: what happened at EPRX last week (0826-0830)?
Weekly Report · 09/02 12:34
More
Webull provides a variety of real-time EPRX stock news. You can receive the latest news about Eupraxia Pharmac through multiple platforms. This information may help you make smarter investment decisions.
About EPRX
Eupraxia Pharmaceuticals Inc. is a Canada-based clinical-stage biotechnology company. The Company is focused on the development of locally delivered, extended-release products. The Company’s lead product candidate, EP-104, is designed to address the significant unmet medical need and market demand for conditions where long-lasting symptom relief is essential to effective treatment. The primary targets for EP-104 have been identified as knee osteoarthritis (OA) and eosinophilic esophagitis (EoE). The product in development for OA is called EP-104IAR and the product in development in EoE is called EP-104GI. DiffuSphere, a proprietary, polymer based micro-sphere technology, is designed to facilitate targeted drug delivery, with extended duration of effect, and offers multiple, highly tunable pharmacokinetic (PK) profiles.